Novel therapeutic strategies following docetaxel-based chemotherapy in castration-resistant prostate cancer

Expert Review of Clinical Pharmacology

Volumn 3, Issue 6, 2010, Pages 785-795

  Fujimoto, Naohiro ^a   Shiota, Masaki ^b   Kubo, Tatsuhiko ^c   Matsumoto, Tetsuro ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

castration resistant; chemotherapy; docetaxel; prostate cancer; second line therapy

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANDROGEN; ANGIOGENESIS INHIBITOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ATRASENTAN; BETA TUBULIN; BEVACIZUMAB; CABAZITAXEL; CAPECITABINE; CEDIRANIB; CLUSTERIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; GIMATECAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; IXABEPILONE; KETOCONAZOLE; MDV 3100; PREDNISONE; SORAFENIB; STAT1 PROTEIN; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; XRP 6258; ZOLEDRONIC ACID;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; HUMAN; MULTIDRUG RESISTANCE; PROSTATE CANCER; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 78649348442     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.10.119     Document Type: Review

References (66)

1. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502-1512 (2004).
2. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351(15), 1513-1520 (2004).
3. Sánchez C, Mendoza P, Contreras HR et al. Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. Prostate 69(13), 1448-1459 (2009).
4. Lee JT Jr, Steelman LS, McCubrey JA. Phosphatidylinositol 3́-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res. 64(22), 8397-8404 (2004).
5. Fabbri F, Brigliadori G, Carloni S et al. Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression. Prostate 70(2), 219-227 (2010).
6. Engels FK, Sparreboom A, Mathot RA, Verweij J. Potential for improvement of docetaxel-based chemotherapy: a pharmacological review. Br. J. Cancer 93(2), 173-177 (2005).
7. Sartor AQ, Oudard S, Ozguroglu M et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: fnal results of a multinational Phase III trial (TROPIC). Presented at: 2010 Genitourinary Cancers Symposium. San Francisco, CA, USA, 5-7 March 2010 (Abstract 9).
8. Hara T, Ushio K, Nishiwaki M et al. A mutation in b-tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel-resistant prostate cancer cell line. Cell Biol. Int. 34(2), 177-184 (2010).
9. Ferrandina G, Zannoni GF, Martinelli E et al. Class III b-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin. Cancer Res. 12(9), 2774-2779 (2006).
10. Gan PP, Pasquier E, Kavallaris M. Class III b-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res. 67(19), 9356-9363 (2007).
11. Galmarini CM, Treilleux I, Cardoso F et al. Class III b-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin. Cancer Res. 14(14), 4511-4516 (2008).
12. Seve P, Dumontet C. Is class III b-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 9(2), 168-175 (2008).
13. Kamath K, Wilson L, Cabral F, Jordan MA. bIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J. Biol. Chem. 280(13), 12902-12907 (2005).
14. Shalli K, Brown I, Heys SD, Schofeld AC. Alterations of b-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J. 19(10), 1299-1301 (2005).
15. Terry S, Ploussard G, Allory Y et al. Increased expression of class III b-tubulin in castration-resistant human prostate cancer. Br. J. Cancer 101(6), 951-956 (2009).
16. Rivera E, Lee J, Davies A et al. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist 13(12), 1207-1223 (2008).
17. Trougakos IP, Djeu JY, Gonos ES, Boothman DA. Advances and challenges in basic and translational research on clusterin. Cancer Res. 69(2), 403-406 (2009).
18. Sowery RD, Hadaschik BA, So AI et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. Br. J. Urol. Int. 102(3), 389-397 (2008).
19. Patterson SG, Wei S, Chen X et al. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 25(45), 6113-6122 (2006).
20. Domingo-Domenech J, Oliva C, Rovira A et al. Interleukin 6, a nuclear factor-kB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin. Cancer Res. 12(18), 5578-5586 (2006).
21. Pchejetski D, Golzio M, Bonhoure E et al. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res. 65(24), 11667-11675 (2005).
22. Sauer L, Nunes J, Salunkhe V et al. Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel. Int. J. Cancer 125(11), 2728-2736 (2009).
23. Zemskova M, Sahakian E, Bashkirova S. The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J. Biol. Chem. 283(30), 20635-20644 (2009).
24. Qian DZ, Rademacher BL, Pittsenbarger J et al. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate 70(4), 433-442 (2010).
25. Zhao L, Lee BY, Brown DA et al. Identifcation of candidate biomarkers of therapeutic response to docetaxel by proteomic profling. Cancer Res. 69(19), 7696-7703 (2009).
26. Bagnato A, Rosanò L. The endothelin axis in cancer. Int. J. Biochem. Cell Biol. 40(8), 1443-1451 (2008).
27. Banerjee S, Hussain M, Wang Z et al. In vitro and in vivo molecular evidence for better therapeutic effcacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res. 67(8), 3818-3826 (2007).
28. Vaishampayan UN, Marur S, Heilbrun LK et al. Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer. J. Urol. 182(1), 317-323 (2009).
29. Goffnet M, Thoulouzan M, Pradines A et al. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer 6, 60 (2006).
30. Coxon JP, Oades GM, Kirby RS, Colston K W. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. Br. J. Urol. Int. 94(1), 164-170 (2004).
31. Fujimoto N, Han B, Kobayashi M, Matsumoto T. Inhibition of geranylgeranylation in the mevalonate pathway inhibits the growth of prostate cancer cells; a novel therapeutic target of prostate cancer. J. Urol. 181(4), 51 (2009) (Abstract 141).
32. Pili R, Rosenthal M. AS1404-203 study group investigators. Addition of DMXAA (ASA404) to docetaxel in patients with hormone-refractory metastatic prostate cancer (HRMPC): update from a randomized Phase II study. J. Clin. Oncol. 26(Suppl.), 15S (2008) (Abstract 5007).
33. Green C, Djeha H, Ireson C, Kelland LR. Consistent marked potentiation of the in vivo antitumor activity of taxanes by the vascular disrupting agent, DMXAA, in lung, ovarian and prostate cancer xenografts. Proc. Am. Assoc. Cancer Res. 47. (2006) (Abstract 514).
34. Aragon-Ching JB, Jain L, Gulley JL et al. Final ana lysis of a Phase II trial using sorafenib for metastatic castration-resistant prostate cancer. Br. J. Urol. Int. 103(12), 1636-1640 (2009).
35. Karakunnel JJ, Gulley JL, Arlen P et al. Cediranib (AZD2171) in docetaxel-resistant, castration-resistant prostate cancer (CRPC). J. Clin. Oncol. 27(Suppl.), S15 (2009) (Abstract 5141).
36. Kelly WK, Halabi S, Carducci MA et al. A randomized, double-blind, placebo-controlled Phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J. Clin. Oncol. 28(Suppl), S7 (2010) (Abstract LBA4511).
37. Di Lorenzo G, Figg W, Fossa S et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a Phase 2 study Eur. Urol. 54(5), 1089-1096 (2008).
38. Heidenreich A, Pfster DJ, Thüer D, Brehmer B. Docetaxel versus docetaxel plus bevacizumab in progressive castration-resistant prostate cancer following frst-line docetaxel. J. Clin. Oncol. 28(Suppl.), S7 (2010) (Abstract e15006).
39. Dahut WL, Scripture C, Posadas E et al. A Phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin. Cancer Res. 14(1), 209-214 (2008).
40. Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928), 787-790 (2009).
41. Scher HI, Beer TM, Higano CS et al. Antitumor activity of MDV3100 in castration-resistant prostate cancer: a Phase 1-2 study. Lancet 375(9724), 1437-1446 (2010).
42. Nakabayashi M, Oh WK, Jacobus S et al. Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer. Br. J. Urol. Int. 105(10), 1392-1396 (2009).
43. Jean GW, Shah, S Keisner SV, Gressett Ussery SM, Dowell J. Response to ketoconazole after failure of docetaxel in patients with advanced androgen-independent prostate cancer (AIPC). J. Clin. Oncol. 28(Suppl.), (2010) (Abstract e15052).
44. Talebi T, Manoharan M, Soloway MS, Singal R. High-dose ketoconazole in castration-resistant, metastatic prostate cancer patients previously treated with docetaxel chemotherapy: single institution retrospective review. J. Clin. Oncol. 28(Suppl.), (2010) (Abstract e15151).
45. Reid AH, Attard G, Danila D et al. A multicenter Phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts). J. Clin. Oncol. 27(Suppl.), S15 (2009) (Abstract 5047).
46. Trump DL, Payne H, Miller K et al. Safety and effcacy of the specifc endothelin A receptor antagonist zibotentan (ZD4054) plus docetaxel in patients with metastatic hormone-resistant prostate cancer: results of a Phase I study. Presented at: 2010 Genitourinary Cancers Symposium. San Francisco, CA, USA, 5-7 March 2010 (Abstract 193).
47. James ND, Caty A, Borre M et al. Safety and effcacy of the specifc endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, Phase 2 trial. Eur. Urol. 55(5), 1112-1123 (2009).
48. Caffo O, Sava T, Comploj E et al. Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone. Urol. Oncol. 28(2), 152-156 (2010).
49. Berger ER, Ciuleanu T, Hart L et al. Results of a randomized Phase II study of irofulven in hormone-refractory prostate cancer patients that have failed frst-line docetaxel treatment J. Clin. Oncol. 25(185 Suppl.), (2007) (Abstract 5068).
50. Thomas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J. Clin. Oncol. 25(33), 5210-5217 (2007).
51. Rosenberg JE, Weinberg VK, Kelly WK et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized Phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 110(3), 556-563 (2007).
52. Beardsley EK, Saad F, Eigl B et al. A Phase II study of patupilone in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel. J. Clin. Oncol. 27(Suppl.), S15 (2009) (Abstract 5139).
53. Pivot X, Koralewski P, Hidalgo JL et al. A multicenter Phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann. Oncol. 19(9), 1547-1552 (2008).
54. Nakabayashi M, Ling J, Xie W, Regan MM, Oh WK. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. Cancer J. 13(2), 125-129 (2007).
55. Ross RW, Beer TM, Jacobus S et al. A Phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 112(3), 521-526 (2008).
56. Nakabayashi M, Sartor O, Jacobus S et al. Response to docetaxel/carboplatin-based chemotherapy as frst-and second-line therapy in patients with metastatic hormone-refractory prostate cancer. Br. J. Urol. Int. 101(3), 308-312 (2008).
57. Reuter CW, Gruenwald V, Ivanyi P, Morgan MA, Fenner M, Ganser A. Carboplatin plus weekly docetaxel as second-line chemotherapy in docetaxel-resistant and castration-resistant prostate cancer (CRPC). J. Clin. Oncol. 28(Suppl.), S7 (2010) (Abstract 4682).
58. Loriot Y, Massard C, Gross-Goupil M et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann. Oncol. 20(4), 703-708 (2009).
59. Wosikowski K, Caligiuri MG, Kaplan F et al. Evaluation of the effcacy of satraplatin (JM216) and its major metabolite JM118 in drug resistant cells and in combination with docetaxel. Proc. Am. Assoc. Cancer Res. 46, (2005) (Abstract 1387).
60. Cora N. Sternberg, Daniel P et al. Multinational, double-blind, Phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J. Clin. Oncol. 27(32), 5431-5438 (2009).
61. Petrylak DP, Sartor AO, Witjes F et al. Survival beneft in do cetaxel-refr actor y androgen independent prostate cancer (AIPC) patients receiving second-line satraplatin in the SPARC trial. Presented at: 2009 Genitourinary Cancers Symposium. Orlando, FL, USA, 26-28 February 2009 (Abstract 163).
62. Saad F, Hotte SJ, North SA et al. A Phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1st-line docetaxel therapy. J. Clin. Oncol. 26(Suppl.), S200 (2008) (Abstract 5002).
63. Eymard S, Oudard G, Gravis J et al Second-line chemotherapy with docetaxel (D) in men treated with docetaxel-based regimen for metastatic hormone-refractory prostate cancer (mHRPC). Presented at: 2007 Prostate Cancer Symposium. Orlando, FL, USA, 22-24 February 2007 (Abstract 249).
64. Ansari J, Hussain SA, Zarkar A et al Docetaxel retreatment for metastatic hormone refractory prostate cancer. J. Clin. Oncol. 26(Suppl.), S200 (2008) (Abstract 16066).
65. Gernone A, Pagliarulo A, Pagliarulo V. Retreatment with docetaxel in metastatic castration-resistant prostate cancer (CRPC). J. Clin. Oncol. 28(Suppl.), (2010) (Abstract e16020).
66. Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M. Prediction of survival following frst-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin. Cancer Res. 16(1), 203-211 (2010).